Chronic Prostatitis Collaborative Research Network Clinical Trial- Ciprofloxacin and Tamsulosin

Condition:   Chronic Prostatitis With Chronic Pelvic Pain Syndrome Interventions:   Drug: Ciprofloxacin;   Drug: Tamsulosin Hydrochloride;   Drug: Tamsulosin Hydrochloride Placebo;   Drug: Ciprofloxacin placebo Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

By KEN TERRY In a recent podcast about the future of telehealth, Lyle Berkowitz, MD, a technology consultant, entrepreneur, and professor at Northwestern University’s Feinberg School of Medicine, confidently predicted that, because of telehealth and clinical automation, “In 10-20 years, we won’t need primary care physicians [for routine care]. The remaining PCPs will specialize in caring for complicated patients. Other than that, if people need care, they’ll go to NPs or PAs or receive automated care with the help of AI.” Berkowitz isn’t the first to make this kind of predictio...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Artificial Intelligence Health Tech AI Ken Terry primary care Source Type: blogs
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
AbstractAccumulating evidence has elucidated that human mesenchymal stem cells (hMSCs) exert profound analgesic effects on numerous animal models of neuropathic pain, including drug-induced peripheral nerves, diabetes-induced neuropathy, and chronic constriction injury. We aimed to address whether forcing expression of sirtuin 1 (SIRT1) can enhance the efficacy of hMSCs on alleviation of pain sensation. A rat model of chronic constriction injury (CCI) mimicking peripheral nerve injury was incorporated in the study. Paw withdrawal threshold (PWT) and paw withdrawal latency (PWL) testing were used to measure pain-related beh...
Source: Journal of Molecular Neuroscience - Category: Neuroscience Source Type: research
Today's review paper is a look at views on aging on the other side of the world, a counterpoint to commentaries from US and European sources. It is interesting to compare the intersection between science and policy in different regions of the world, when it comes to perspectives on degenerative aging, the enormous costs of age-related disease, and what is to be done about it. It is only comparatively recently that scientific advances have offered the potential for aging to become anything other than an inevitable, enormous cost to be suffered. Governments with entrenched and growing entitlement programs (such as the US Soc...
Source: Fight Aging! - Category: Research Authors: Tags: Politics and Legislation Source Type: blogs
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glob...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
CONCLUSIONS: Small sample sizes, limited numbers of RCTs per condition, variation in outcome measures, and poor reporting of the included RCTs mean no definitive conclusions regarding the efficacy or safety of pine bark extract supplements are possible. PMID: 32990945 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
Researchers here note that delivering metformin via injection rather than the usual oral administration removes unwanted side-effects and better improves cognitive function in old mice. Near all testing of metformin has used oral administration, and the effects on pace of aging and life span are, frankly, too unreliable and too small to justify the present level of interest in the drug on the part of the longevity community. Administration by injection might be a different story, but waiting on further research and confirming data would be a wiser course of action than immediate excitement. Even then, this is tinkering wit...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
We describe the synergy between ORPRN projects and ECHO programs using 3 examples: tobacco cessation, chronic pain and opioid prescribing, and diabetes management. We highlight challenges and opportunities in these examples, beginning with their development, their implementation, and their ultimate alignment, despite varied funding streams and timelines. We believe that incorporating the OEN within ORPRN has been a success for both PBRN research and Project ECHO programs, allowing us to better support primary care practices across the state.
Source: Journal of the American Board of Family Medicine - Category: Primary Care Authors: Tags: Family Medicine and the Health Care System Source Type: research
ConclusionComplications frequently occur in EPN patients as compared to pyelonephritis.
Source: Journal of Diabetes and Metabolic Disorders - Category: Endocrinology Source Type: research
Funding Opportunity RFA-DK-20-505 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites an application for the Scientific Data Research Center (SDRC) of the Gastroparesis Clinical Research Consortium (GpCRC). The companion FOA, RFA-DK-20-504 will support continuation of the GpCRC Clinical Centers (CC). The Consortium forms a multi-disciplinary teams composed of members from the CCs and SDRC to undertake a comprehensive clinical, epidemiological and biological characterization of adult and children patients with GP to gain insight into the pathophysiology of GP and its sequela: ch...
Source: NIH Funding Opportunities (Notices, PA, RFA) - Category: Research Source Type: funding
More News: Chronic Pain | Cipro | Ciprofloxacin | Clinical Trials | Diabetes | Endocrinology | Pain | Research | Urology & Nephrology